Hologic, Inc.
General ticker "HOLX" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $14.9B (TTM average)
Hologic, Inc. follows the US Stock Market performance with the rate: 56.7%.
Estimated limits based on current volatility of 0.2%: low 75.09$, high 75.36$
Factors to consider:
- Company included in S&P500 list
- Total employees count: 7063 (+1.0%) as of 2024
- US accounted for 76.9% of revenue in the fiscal year ended 2023-09-30
- Top business risk factors: Pandemic risks, Supply chain disruptions, Product liability, Regulatory and compliance, Integration challenges
- Price in estimated range
- Earnings for 3 months up through Q1 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-09-27 to 2027-09-27
- 2025-09-27 to 2026-09-27 estimated range: [59.00$, 81.44$]
- 2026-09-27 to 2027-09-27 estimated range: [64.72$, 88.02$]
Financial Metrics affecting the HOLX estimates:
- Negative: with PPE of 15.6 at the end of fiscal year the price was high
- Positive: 7.67 < Operating profit margin, % of 17.42
- Positive: 6.64 < Operating cash flow per share per price, % of 7.00
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 5.90
- Negative: 0 < Inventory ratio change, % of 0.09
- Positive: 42.68 < Shareholder equity ratio, % of 56.00 <= 64.29
- Positive: -0.01 < Industry operating cash flow per share per price (median), % of 1.49
- Positive: Interest expense per share per price, % of 0.28 <= 0.73
Short-term HOLX quotes
Relationship graph
Long-term HOLX plot with estimates
Financial data
| YTD | 2023-09-30 | 2024-09-30 | 2025-09-27 |
|---|---|---|---|
| Operating Revenue | $3,978.70MM | $4,030.30MM | $4,100.50MM |
| Operating Expenses | $3,310.30MM | $3,147.70MM | $3,386.20MM |
| Operating Income | $668.40MM | $882.60MM | $714.30MM |
| Non-Operating Income | $7.70MM | $-17.50MM | $-33.10MM |
| Interest Expense | $111.10MM | $122.10MM | $42.70MM |
| R&D Expense | $294.30MM | $272.80MM | $248.20MM |
| Income(Loss) | $676.10MM | $865.10MM | $681.20MM |
| Taxes | $220.10MM | $75.60MM | $115.50MM |
| Profit(Loss)* | $456.00MM | $789.50MM | $565.70MM |
| Stockholders Equity | $5,016.90MM | $5,130.00MM | $5,047.90MM |
| Inventory | $617.60MM | $679.80MM | $679.40MM |
| Assets | $9,139.30MM | $9,156.00MM | $9,014.90MM |
| Operating Cash Flow | $1,051.20MM | $1,285.20MM | $1,057.10MM |
| Capital expenditure | $150.20MM | $140.20MM | $137.00MM |
| Investing Cash Flow | $-152.10MM | $-781.00MM | $-482.70MM |
| Financing Cash Flow | $-483.20MM | $-1,108.60MM | $-777.20MM |
| Earnings Per Share** | $1.85 | $3.35 | $2.49 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.